Related Experiment Video
Updated: Jan 29, 2026

Optogenetic Activation of Afferent Pathways in Brain Slices and Modulation of Responses by Volatile Anesthetics
Published on: July 23, 2020
Directional Modulation of the Integrated Stress Response in Neurodegeneration: A Systematic Review of eIF2B
Isabella Ionela Stoian1,2, Daciana Nistor3,4, Mihaela Codrina Levai1,5,6
1Doctoral School, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania.
Abstract:
Background and Objectives: The integrated stress response (ISR) is a convergent node in neurodegeneration. We systematically mapped open-access mammalian in vivo evidence for synthetic ISR modulators, comparing efficacy signals, biomarker engagement, and safety across mechanisms and disease classes. Methods: Following PRISMA 2020, we searched PubMed (MEDLINE), Embase, and Scopus from inception to 22 September 2025. Inclusion required mammalian neurodegeneration models; synthetic ISR modulators (eIF2B activators, PERK inhibitors or activators, GADD34-PP1 ISR prolongers); prespecified outcomes; and full open access. Extracted data included model, dose and route, outcomes, translational biomarkers (ATF4, phosphorylated eIF2α), and safety. Results: Twelve studies met the criteria across tauopathies and Alzheimer's disease (n = 5), prion disease (n = 1), amyotrophic lateral sclerosis and Huntington's disease (n = 3), hereditary neuropathies (n = 2), demyelination (n = 1), and aging (n = 1). Among interpretable in vivo entries, 10 of 11 reported benefit in at least one domain. By class, eIF2B activation with ISRIB was positive in three of four studies, with one null Alzheimer's hAPP-J20 study; PERK inhibition was positive in all three studies; ISR prolongation with Sephin1 or IFB-088 was positive in both studies; and PERK activation was positive in both studies. Typical regimens included ISRIB 0.1-2.5 mg per kg given intraperitoneally (often two to three doses) with reduced ATF4 and phosphorylated eIF2α; oral GSK2606414 50 mg per kg twice daily for six to seven weeks, achieving brain-level exposures; continuous MK-28 delivery at approximately 1 mg per kg; and oral IFB-088 or Sephin1 given over several weeks. Safety was mechanism-linked: systemic PERK inhibition produced pancreatic and other exocrine toxicities at higher exposures, whereas ISRIB and ISR-prolonging agents were generally well-tolerated in the included reports. Conclusions: Directional ISR control yields consistent, context-dependent improvements in behavior, structure, or survival, with biomarker evidence of target engagement. Mechanism matching (down-tuning versus prolonging the ISR) and exposure-driven safety management are central for translation.
Insights
Synthetic modulators of the integrated stress response (ISR) show promise for neurodegenerative diseases. Targeting the ISR pathway offers consistent benefits, but mechanism and safety must be carefully managed for effective translation.
Area of Science:
- Neuroscience
- Pharmacology
- Genetics
Background:
- The integrated stress response (ISR) is a key pathway implicated in neurodegenerative diseases.
- Synthetic modulators offer potential therapeutic strategies for these conditions.
- Understanding their efficacy, biomarker engagement, and safety is crucial for clinical translation.
Purpose of the Study:
- To systematically map and compare the in vivo evidence for synthetic ISR modulators in mammalian neurodegeneration models.
- To assess efficacy signals, biomarker engagement (e.g., ATF4, p-eIF2α), and safety profiles across different ISR modulation mechanisms and disease classes.
Main Methods:
- A systematic literature search was conducted following PRISMA 2020 guidelines across PubMed, Embase, and Scopus.
- Inclusion criteria comprised mammalian neurodegeneration models, synthetic ISR modulators (eIF2B activators, PERK inhibitors/activators, GADD34-PP1 prolongers), and prespecified outcomes.
- Data extracted included model details, dosage, route, outcomes, translational biomarkers, and safety information.
Main Results:
- Twelve studies met the criteria, covering Alzheimer's disease, prion disease, ALS, Huntington's disease, neuropathies, demyelination, and aging.
- Ten of eleven interpretable studies reported benefits in at least one domain.
- Different modulator classes showed varied efficacy: eIF2B activation (ISRIB) was positive in 3/4 studies, PERK inhibition in all 3, ISR prolongation in both, and PERK activation in both.
- Safety profiles were mechanism-dependent, with PERK inhibition showing toxicities, while ISRIB and ISR-prolonging agents were generally well-tolerated.
Conclusions:
- Directional control of the ISR pathway leads to consistent, context-dependent improvements in behavior, structure, or survival, supported by biomarker evidence.
- Matching the ISR modulation mechanism (down-tuning vs. prolonging) to the specific disease context is essential.
- Exposure-driven safety management is critical for the successful translation of ISR modulators into clinical therapies.
Related Concept Videos
Responses to Heat and Cold Stress
Responses to Salt Stress
Direct Motor Pathways
The corticospinal tract is responsible for the voluntary movement of the limbs and trunk. It originates in the cerebral cortex of the brain and descends through the cerebrum's internal capsule and...
Stress Response System
Alarm stage
In the alarm stage, the body's...
Psychological Responses to Stress
Other Stress Responses in Bacteria

